Traboulsee A - Search Results

1

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. Among authors: traboulsee a. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.

2

The role of MRI in the diagnosis of multiple sclerosis.

Traboulsee AL, Li DK. Traboulsee AL, et al. Adv Neurol. 2006;98:125-46. Adv Neurol. 2006. PMID: 16400831 Review.

3

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS. Simon JH, et al. Among authors: traboulsee a. AJNR Am J Neuroradiol. 2006 Feb;27(2):455-61. AJNR Am J Neuroradiol. 2006. PMID: 16484429 Free PMC article. No abstract available.

4

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. Kappos L, et al. Among authors: traboulsee a. Neurology. 2006 Sep 26;67(6):944-53. doi: 10.1212/01.wnl.0000237994.95410.ce. Neurology. 2006. PMID: 17000959 Clinical Trial.

5

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; BENEFIT investigators. Polman C, et al. J Neurol. 2008 Apr;255(4):480-7. doi: 10.1007/s00415-007-0733-2. Epub 2007 Nov 15. J Neurol. 2008. PMID: 18004635 Clinical Trial.

6

MR relaxation in multiple sclerosis.

MacKay AL, Vavasour IM, Rauscher A, Kolind SH, Mädler B, Moore GR, Traboulsee AL, Li DK, Laule C. MacKay AL, et al. Among authors: traboulsee al. Neuroimaging Clin N Am. 2009 Feb;19(1):1-26. doi: 10.1016/j.nic.2008.09.007. Neuroimaging Clin N Am. 2009. PMID: 19064196 Review.

7

Does MRI lesion activity regress in secondary progressive multiple sclerosis?

Zhao Y, Petkau AJ, Traboulsee A, Riddehough A, Li DK. Zhao Y, et al. Among authors: traboulsee a. Mult Scler. 2010 Apr;16(4):434-42. doi: 10.1177/1352458509359726. Epub 2010 Feb 18. Mult Scler. 2010. PMID: 20167592

8

Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis.

Laule C, Vavasour IM, Zhao Y, Traboulsee AL, Oger J, Vavasour JD, Mackay AL, Li DK. Laule C, et al. Among authors: traboulsee al. Mult Scler. 2010 Jun;16(6):670-7. doi: 10.1177/1352458510365586. Mult Scler. 2010. PMID: 20558500 Clinical Trial.

9

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.

Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. Uitdehaag B, et al. Among authors: traboulsee a. Ther Adv Neurol Disord. 2011 Jan;4(1):3-14. doi: 10.1177/1756285610391693. Ther Adv Neurol Disord. 2011. PMID: 21339904 Free PMC article.

10

Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Bar-Or A, Rieckmann P, Traboulsee A, Yong VW. Bar-Or A, et al. Among authors: traboulsee a. CNS Drugs. 2011 Sep 1;25(9):783-99. doi: 10.2165/11587820-000000000-00000. CNS Drugs. 2011. PMID: 21870889 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

257 results

Search Page